#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Brief
2-1	4-9	Brief	_	_	_	_

#Text=Overview of the Established Practice in Determining the Amino Acid Composition of the CHO Cell Medium
3-1	10-18	Overview	abstract[2]	new[2]	_	_
3-2	19-21	of	abstract[2]	new[2]	_	_
3-3	22-25	the	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-4	26-37	Established	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-5	38-46	Practice	abstract[2]|abstract[3]	new[2]|new[3]	_	_
3-6	47-49	in	_	_	_	_
3-7	50-61	Determining	_	_	_	_
3-8	62-65	the	abstract[5]	new[5]	coref	4-4[11_5]
3-9	66-71	Amino	abstract[5]	new[5]	_	_
3-10	72-76	Acid	person|abstract[5]	new|new[5]	_	_
3-11	77-88	Composition	abstract[5]	new[5]	_	_
3-12	89-91	of	abstract[5]	new[5]	_	_
3-13	92-95	the	abstract[5]|object[8]	new[5]|new[8]	_	_
3-14	96-99	CHO	abstract[5]|abstract|object[8]	new[5]|new|new[8]	coref	4-9
3-15	100-104	Cell	abstract[5]|person|object[8]	new[5]|new|new[8]	_	_
3-16	105-111	Medium	abstract[5]|object[8]	new[5]|new[8]	_	_

#Text=Reports on improving the culture medium composition for CHO cells , specifically in relation to the amino acids , are relatively limited in number .
4-1	112-119	Reports	abstract	new	coref	5-4
4-2	120-122	on	_	_	_	_
4-3	123-132	improving	_	_	_	_
4-4	133-136	the	abstract[11]	giv[11]	coref	20-40[155_11]
4-5	137-144	culture	abstract|abstract[11]	new|giv[11]	coref	17-19[125_0]
4-6	145-151	medium	abstract[11]	giv[11]	_	_
4-7	152-163	composition	abstract[11]	giv[11]	_	_
4-8	164-167	for	abstract[11]	giv[11]	_	_
4-9	168-171	CHO	abstract[11]|substance|object[13]	giv[11]|giv|new[13]	coref|coref|coref|coref	5-18|5-18[23_13]|5-18|5-18[23_13]
4-10	172-177	cells	abstract[11]|object[13]	giv[11]|new[13]	_	_
4-11	178-179	,	_	_	_	_
4-12	180-192	specifically	abstract[14]	new[14]	_	_
4-13	193-195	in	abstract[14]	new[14]	_	_
4-14	196-204	relation	abstract[14]	new[14]	_	_
4-15	205-207	to	abstract[14]	new[14]	_	_
4-16	208-211	the	abstract[14]|substance[16]	new[14]|new[16]	coref	9-30[42_16]
4-17	212-217	amino	abstract[14]|object|substance[16]	new[14]|new|new[16]	coref	9-30
4-18	218-223	acids	abstract[14]|substance[16]	new[14]|new[16]	_	_
4-19	224-225	,	_	_	_	_
4-20	226-229	are	_	_	_	_
4-21	230-240	relatively	_	_	_	_
4-22	241-248	limited	_	_	_	_
4-23	249-251	in	_	_	_	_
4-24	252-258	number	abstract	new	coref	9-22[39_0]
4-25	259-260	.	_	_	_	_

#Text=This paucity of reports is strikingly unusual especially considering the widespread use and vast economic importance of CHO cells .
5-1	261-265	This	abstract[18]	new[18]	_	_
5-2	266-273	paucity	abstract[18]	new[18]	_	_
5-3	274-276	of	abstract[18]	new[18]	_	_
5-4	277-284	reports	abstract[18]|abstract	new[18]|giv	_	_
5-5	285-287	is	_	_	_	_
5-6	288-298	strikingly	_	_	_	_
5-7	299-306	unusual	_	_	_	_
5-8	307-317	especially	_	_	_	_
5-9	318-329	considering	_	_	_	_
5-10	330-333	the	abstract[20]	new[20]	_	_
5-11	334-344	widespread	abstract[20]	new[20]	_	_
5-12	345-348	use	abstract[20]	new[20]	_	_
5-13	349-352	and	_	_	_	_
5-14	353-357	vast	abstract[21]	new[21]	_	_
5-15	358-366	economic	abstract[21]	new[21]	_	_
5-16	367-377	importance	abstract[21]	new[21]	_	_
5-17	378-380	of	abstract[21]	new[21]	_	_
5-18	381-384	CHO	abstract[21]|substance|object[23]	new[21]|giv|giv[23]	coref|coref|coref|coref	9-6|9-6[33_23]|9-6|9-6[33_23]
5-19	385-390	cells	abstract[21]|object[23]	new[21]|giv[23]	_	_
5-20	391-392	.	_	_	_	_

#Text=2.1 .
6-1	393-396	2.1	abstract	new	_	_
6-2	397-398	.	_	_	_	_

#Text=Statistical Methods : Utilizing Data-Driven Models in Experimental Design
7-1	399-410	Statistical	abstract[25]	new[25]	coref	22-9[169_25]
7-2	411-418	Methods	abstract[25]	new[25]	_	_
7-3	419-420	:	_	_	_	_
7-4	421-430	Utilizing	_	_	_	_
7-5	431-442	Data-Driven	person[26]	new[26]	_	_
7-6	443-449	Models	person[26]	new[26]	_	_
7-7	450-452	in	_	_	_	_
7-8	453-465	Experimental	abstract[27]	new[27]	coref	8-1[28_27]
7-9	466-472	Design	abstract[27]	new[27]	_	_

#Text=Statistical design , also known as design-of-experiments , is arguably the most commonly employed strategy for medium development .
8-1	473-484	Statistical	abstract[28]	giv[28]	coref	8-10[29_28]
8-2	485-491	design	abstract[28]	giv[28]	_	_
8-3	492-493	,	_	_	_	_
8-4	494-498	also	_	_	_	_
8-5	499-504	known	_	_	_	_
8-6	505-507	as	_	_	_	_
8-7	508-529	design-of-experiments	_	_	_	_
8-8	530-531	,	_	_	_	_
8-9	532-534	is	_	_	_	_
8-10	535-543	arguably	abstract[29]	giv[29]	coref	13-7[0_29]
8-11	544-547	the	abstract[29]	giv[29]	_	_
8-12	548-552	most	abstract[29]	giv[29]	_	_
8-13	553-561	commonly	abstract[29]	giv[29]	_	_
8-14	562-570	employed	abstract[29]	giv[29]	_	_
8-15	571-579	strategy	abstract[29]	giv[29]	_	_
8-16	580-583	for	abstract[29]	giv[29]	_	_
8-17	584-590	medium	abstract[29]|event[30]	giv[29]|new[30]	ana	9-13[35_30]
8-18	591-602	development	abstract[29]|event[30]	giv[29]|new[30]	_	_
8-19	603-604	.	_	_	_	_

#Text=Unfortunately most such studies for CHO cells focus on components such as those relevant for the carbon and energy metabolism with only a limited number of studies specifically addressing amino acids .
9-1	605-618	Unfortunately	event[31]	new[31]	coref	9-27[0_31]
9-2	619-623	most	event[31]	new[31]	_	_
9-3	624-628	such	event[31]	new[31]	_	_
9-4	629-636	studies	event[31]	new[31]	_	_
9-5	637-640	for	event[31]	new[31]	_	_
9-6	641-644	CHO	event[31]|substance|object[33]	new[31]|giv|giv[33]	coref|coref|coref|coref	11-18|11-16[60_33]|11-18|11-16[60_33]
9-7	645-650	cells	event[31]|object[33]	new[31]|giv[33]	_	_
9-8	651-656	focus	_	_	_	_
9-9	657-659	on	_	_	_	_
9-10	660-670	components	abstract[34]	new[34]	_	_
9-11	671-675	such	abstract[34]	new[34]	_	_
9-12	676-678	as	abstract[34]	new[34]	_	_
9-13	679-684	those	abstract[34]|event[35]	new[34]|giv[35]	coref	10-19[47_35]
9-14	685-693	relevant	abstract[34]|event[35]	new[34]|giv[35]	_	_
9-15	694-697	for	_	_	_	_
9-16	698-701	the	substance[36]	new[36]	_	_
9-17	702-708	carbon	substance[36]	new[36]	_	_
9-18	709-712	and	_	_	_	_
9-19	713-719	energy	substance|abstract[38]	new|new[38]	coref|coref	14-16[93_38]|14-16[93_38]
9-20	720-730	metabolism	abstract[38]	new[38]	_	_
9-21	731-735	with	abstract[38]	new[38]	_	_
9-22	736-740	only	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-23	741-742	a	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-24	743-750	limited	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-25	751-757	number	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-26	758-760	of	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
9-27	761-768	studies	abstract[38]|abstract[39]|event	new[38]|giv[39]|giv	coref	21-6[157_0]
9-28	769-781	specifically	_	_	_	_
9-29	782-792	addressing	_	_	_	_
9-30	793-798	amino	object|substance[42]	giv|giv[42]	coref|coref|coref|coref	12-1[61_0]|13-14[79_42]|12-1[61_0]|13-14[79_42]
9-31	799-804	acids	substance[42]	giv[42]	_	_
9-32	805-806	.	_	_	_	_

#Text=In line with this observation for statistical methodologies , search heuristics such as genetic algorithms commonly employed in medium development and optimization in various organisms have not been utilized for improving CHO cell medium compositions , even the chemically defined cell-free formulations .
10-1	807-809	In	_	_	_	_
10-2	810-814	line	_	_	_	_
10-3	815-819	with	_	_	_	_
10-4	820-824	this	abstract[43]	new[43]	_	_
10-5	825-836	observation	abstract[43]	new[43]	_	_
10-6	837-840	for	abstract[43]	new[43]	_	_
10-7	841-852	statistical	abstract[43]|abstract[44]	new[43]|new[44]	_	_
10-8	853-866	methodologies	abstract[43]|abstract[44]	new[43]|new[44]	_	_
10-9	867-868	,	_	_	_	_
10-10	869-875	search	_	_	_	_
10-11	876-886	heuristics	abstract[45]	new[45]	_	_
10-12	887-891	such	abstract[45]	new[45]	_	_
10-13	892-894	as	abstract[45]	new[45]	_	_
10-14	895-902	genetic	abstract[45]|abstract[46]	new[45]|new[46]	_	_
10-15	903-913	algorithms	abstract[45]|abstract[46]	new[45]|new[46]	_	_
10-16	914-922	commonly	_	_	_	_
10-17	923-931	employed	_	_	_	_
10-18	932-934	in	_	_	_	_
10-19	935-941	medium	event[47]	giv[47]	coref	22-41[0_47]
10-20	942-953	development	event[47]	giv[47]	_	_
10-21	954-957	and	_	_	_	_
10-22	958-970	optimization	abstract[48]	new[48]	coref	19-13[136_48]
10-23	971-973	in	abstract[48]	new[48]	_	_
10-24	974-981	various	abstract[48]|animal[49]	new[48]|new[49]	_	_
10-25	982-991	organisms	abstract[48]|animal[49]	new[48]|new[49]	_	_
10-26	992-996	have	_	_	_	_
10-27	997-1000	not	_	_	_	_
10-28	1001-1005	been	_	_	_	_
10-29	1006-1014	utilized	_	_	_	_
10-30	1015-1018	for	_	_	_	_
10-31	1019-1028	improving	_	_	_	_
10-32	1029-1032	CHO	object[51]	new[51]	_	_
10-33	1033-1037	cell	place|object[51]	new|new[51]	coref	12-31
10-34	1038-1044	medium	object[51]	new[51]	_	_
10-35	1045-1057	compositions	object[51]	new[51]	_	_
10-36	1058-1059	,	_	_	_	_
10-37	1060-1064	even	substance[52]	new[52]	_	_
10-38	1065-1068	the	substance[52]	new[52]	_	_
10-39	1069-1079	chemically	substance[52]	new[52]	_	_
10-40	1080-1087	defined	substance[52]	new[52]	_	_
10-41	1088-1097	cell-free	substance[52]	new[52]	_	_
10-42	1098-1110	formulations	substance[52]	new[52]	_	_
10-43	1111-1112	.	_	_	_	_

#Text=Low glutamine and high essential amino acid concentrations led to high mAb production against Botulinum A by CHO cells .
11-1	1113-1116	Low	substance[53]	new[53]	coref	12-6[0_53]
11-2	1117-1126	glutamine	substance[53]	new[53]	_	_
11-3	1127-1130	and	_	_	_	_
11-4	1131-1135	high	abstract[55]	new[55]	coref	20-25[148_55]
11-5	1136-1145	essential	abstract[55]	new[55]	_	_
11-6	1146-1151	amino	abstract[55]	new[55]	_	_
11-7	1152-1156	acid	substance|abstract[55]	new|new[55]	coref	12-3
11-8	1157-1171	concentrations	abstract[55]	new[55]	_	_
11-9	1172-1175	led	_	_	_	_
11-10	1176-1178	to	_	_	_	_
11-11	1179-1183	high	abstract[57]	new[57]	coref	12-42[72_57]
11-12	1184-1187	mAb	substance|abstract[57]	new|new[57]	coref	25-17
11-13	1188-1198	production	abstract[57]	new[57]	_	_
11-14	1199-1206	against	_	_	_	_
11-15	1207-1216	Botulinum	substance	new	_	_
11-16	1217-1218	A	object[60]	giv[60]	coref	13-27[86_60]
11-17	1219-1221	by	object[60]	giv[60]	_	_
11-18	1222-1225	CHO	substance|object[60]	giv|giv[60]	coref	14-17
11-19	1226-1231	cells	object[60]	giv[60]	_	_
11-20	1232-1233	.	_	_	_	_

#Text=An amino acid other than glutamine ( analytically uncharacterized ) was identified as the limiting component in a study that employed response surface methodology to evaluate medium-associated effects on viable cell density ( as a proxy for mAb concentration ) during coupled production and growth .
12-1	1234-1236	An	object[61]	giv[61]	coref	16-10[0_61]
12-2	1237-1242	amino	object[61]	giv[61]	_	_
12-3	1243-1247	acid	object[61]|substance	giv[61]|giv	coref	17-13
12-4	1248-1253	other	object[61]	giv[61]	_	_
12-5	1254-1258	than	_	_	_	_
12-6	1259-1268	glutamine	substance	giv	_	_
12-7	1269-1270	(	_	_	_	_
12-8	1271-1283	analytically	_	_	_	_
12-9	1284-1299	uncharacterized	_	_	_	_
12-10	1300-1301	)	_	_	_	_
12-11	1302-1305	was	_	_	_	_
12-12	1306-1316	identified	_	_	_	_
12-13	1317-1319	as	_	_	_	_
12-14	1320-1323	the	_	_	_	_
12-15	1324-1332	limiting	_	_	_	_
12-16	1333-1342	component	_	_	_	_
12-17	1343-1345	in	_	_	_	_
12-18	1346-1347	a	abstract[64]	new[64]	coref	21-39[165_64]
12-19	1348-1353	study	abstract[64]	new[64]	_	_
12-20	1354-1358	that	_	_	_	_
12-21	1359-1367	employed	_	_	_	_
12-22	1368-1376	response	abstract|abstract[67]	new|new[67]	coref|coref|coref|coref	20-35|20-35[153_67]|20-35|20-35[153_67]
12-23	1377-1384	surface	place|abstract[67]	new|new[67]	coref	20-36
12-24	1385-1396	methodology	abstract[67]	new[67]	_	_
12-25	1397-1399	to	_	_	_	_
12-26	1400-1408	evaluate	_	_	_	_
12-27	1409-1426	medium-associated	abstract[68]	new[68]	coref	20-13[145_68]
12-28	1427-1434	effects	abstract[68]	new[68]	_	_
12-29	1435-1437	on	abstract[68]	new[68]	_	_
12-30	1438-1444	viable	abstract[68]|abstract[70]	new[68]|new[70]	coref	15-40[104_70]
12-31	1445-1449	cell	abstract[68]|object|abstract[70]	new[68]|giv|new[70]	coref	14-18
12-32	1450-1457	density	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-33	1458-1459	(	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-34	1460-1462	as	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-35	1463-1464	a	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-36	1465-1470	proxy	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-37	1471-1474	for	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-38	1475-1478	mAb	abstract[68]|abstract[70]|abstract[71]	new[68]|new[70]|new[71]	coref	15-20[99_71]
12-39	1479-1492	concentration	abstract[68]|abstract[70]|abstract[71]	new[68]|new[70]|new[71]	_	_
12-40	1493-1494	)	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-41	1495-1501	during	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-42	1502-1509	coupled	abstract[68]|abstract[70]|abstract[72]	new[68]|new[70]|giv[72]	coref	13-23[83_72]
12-43	1510-1520	production	abstract[68]|abstract[70]|abstract[72]	new[68]|new[70]|giv[72]	_	_
12-44	1521-1524	and	abstract[68]|abstract[70]	new[68]|new[70]	_	_
12-45	1525-1531	growth	abstract[68]|abstract[70]|abstract	new[68]|new[70]|new	coref	13-21
12-46	1532-1533	.	_	_	_	_

#Text=González et al. used the Plackett-Burman design method to optimize the contribution of ten amino acids to the rate of growth and monoclonal antibody production by Chinese hamster ovary cells .
13-1	1534-1542	González	person	new	_	_
13-2	1543-1545	et	_	_	_	_
13-3	1546-1549	al.	_	_	_	_
13-4	1550-1554	used	_	_	_	_
13-5	1555-1558	the	abstract[77]	new[77]	coref	25-1[182_77]
13-6	1559-1574	Plackett-Burman	person|abstract[77]	new|new[77]	coref	20-9
13-7	1575-1581	design	abstract|abstract[77]	giv|new[77]	coref	18-4[128_0]
13-8	1582-1588	method	abstract[77]	new[77]	_	_
13-9	1589-1591	to	_	_	_	_
13-10	1592-1600	optimize	_	_	_	_
13-11	1601-1604	the	abstract[78]	new[78]	_	_
13-12	1605-1617	contribution	abstract[78]	new[78]	_	_
13-13	1618-1620	of	abstract[78]	new[78]	_	_
13-14	1621-1624	ten	abstract[78]|substance[79]	new[78]|giv[79]	coref	14-1[87_79]
13-15	1625-1630	amino	abstract[78]|substance[79]	new[78]|giv[79]	_	_
13-16	1631-1636	acids	abstract[78]|substance[79]	new[78]|giv[79]	_	_
13-17	1637-1639	to	abstract[78]	new[78]	_	_
13-18	1640-1643	the	abstract[78]|quantity[80]	new[78]|new[80]	coref	15-15[98_80]
13-19	1644-1648	rate	abstract[78]|quantity[80]	new[78]|new[80]	_	_
13-20	1649-1651	of	abstract[78]|quantity[80]	new[78]|new[80]	_	_
13-21	1652-1658	growth	abstract[78]|quantity[80]|abstract	new[78]|new[80]|giv	coref	15-11
13-22	1659-1662	and	abstract[78]|quantity[80]	new[78]|new[80]	_	_
13-23	1663-1673	monoclonal	abstract[78]|quantity[80]|abstract[83]	new[78]|new[80]|giv[83]	coref	25-17[188_83]
13-24	1674-1682	antibody	abstract[78]|quantity[80]|substance|abstract[83]	new[78]|new[80]|new|giv[83]	coref	15-51
13-25	1683-1693	production	abstract[78]|quantity[80]|abstract[83]	new[78]|new[80]|giv[83]	_	_
13-26	1694-1696	by	abstract[78]|quantity[80]|abstract[83]	new[78]|new[80]|giv[83]	_	_
13-27	1697-1704	Chinese	abstract[78]|quantity[80]|abstract[83]|object[86]	new[78]|new[80]|giv[83]|giv[86]	coref	18-9[129_86]
13-28	1705-1712	hamster	abstract[78]|quantity[80]|abstract[83]|animal|object[86]	new[78]|new[80]|giv[83]|new|giv[86]	_	_
13-29	1713-1718	ovary	abstract[78]|quantity[80]|abstract[83]|person|object[86]	new[78]|new[80]|giv[83]|new|giv[86]	_	_
13-30	1719-1724	cells	abstract[78]|quantity[80]|abstract[83]|object[86]	new[78]|new[80]|giv[83]|giv[86]	_	_
13-31	1725-1726	.	_	_	_	_

#Text=These 10 amino acids were specifically identified as per their superior uptake and utilization by the CHO cell metabolism .
14-1	1727-1732	These	substance[87]	giv[87]	ana	14-10[0_87]
14-2	1733-1735	10	substance[87]	giv[87]	_	_
14-3	1736-1741	amino	substance[87]	giv[87]	_	_
14-4	1742-1747	acids	substance[87]	giv[87]	_	_
14-5	1748-1752	were	_	_	_	_
14-6	1753-1765	specifically	_	_	_	_
14-7	1766-1776	identified	_	_	_	_
14-8	1777-1779	as	_	_	_	_
14-9	1780-1783	per	_	_	_	_
14-10	1784-1789	their	substance|abstract[89]	giv|new[89]	coref|coref	16-8[114_0]|16-8[114_0]
14-11	1790-1798	superior	abstract[89]	new[89]	_	_
14-12	1799-1805	uptake	abstract[89]	new[89]	_	_
14-13	1806-1809	and	_	_	_	_
14-14	1810-1821	utilization	abstract[90]	new[90]	coref	22-26[175_90]
14-15	1822-1824	by	abstract[90]	new[90]	_	_
14-16	1825-1828	the	abstract[90]|abstract[93]	new[90]|giv[93]	_	_
14-17	1829-1832	CHO	abstract[90]|object|abstract[93]	new[90]|giv|giv[93]	_	_
14-18	1833-1837	cell	abstract[90]|object|abstract[93]	new[90]|giv|giv[93]	coref	15-25
14-19	1838-1848	metabolism	abstract[90]|abstract[93]	new[90]|giv[93]	_	_
14-20	1849-1850	.	_	_	_	_

#Text=The analysis was carried out both during exponential phase of growth through monitoring how the specific growth rate and the concentration of the viable cell concentration evolved over time , and during the phase where the cell population reached a very high density , through monitoring of the final monoclonal antibody product concentration and the specific productivity of the cell population .
15-1	1851-1854	The	abstract[94]	new[94]	_	_
15-2	1855-1863	analysis	abstract[94]	new[94]	_	_
15-3	1864-1867	was	_	_	_	_
15-4	1868-1875	carried	_	_	_	_
15-5	1876-1879	out	_	_	_	_
15-6	1880-1884	both	abstract[95]	new[95]	coref	15-33[101_95]
15-7	1885-1891	during	abstract[95]	new[95]	_	_
15-8	1892-1903	exponential	abstract[95]	new[95]	_	_
15-9	1904-1909	phase	abstract[95]	new[95]	_	_
15-10	1910-1912	of	abstract[95]	new[95]	_	_
15-11	1913-1919	growth	abstract[95]|abstract	new[95]|giv	coref	15-17
15-12	1920-1927	through	_	_	_	_
15-13	1928-1938	monitoring	_	_	_	_
15-14	1939-1942	how	_	_	_	_
15-15	1943-1946	the	quantity[98]	giv[98]	_	_
15-16	1947-1955	specific	quantity[98]	giv[98]	_	_
15-17	1956-1962	growth	abstract|quantity[98]	giv|giv[98]	_	_
15-18	1963-1967	rate	quantity[98]	giv[98]	_	_
15-19	1968-1971	and	_	_	_	_
15-20	1972-1975	the	abstract[99]	giv[99]	coref	15-48[108_99]
15-21	1976-1989	concentration	abstract[99]	giv[99]	_	_
15-22	1990-1992	of	abstract[99]	giv[99]	_	_
15-23	1993-1996	the	abstract[99]	giv[99]	_	_
15-24	1997-2003	viable	abstract[99]	giv[99]	_	_
15-25	2004-2008	cell	abstract[99]|place	giv[99]|giv	coref	15-37
15-26	2009-2022	concentration	abstract[99]	giv[99]	_	_
15-27	2023-2030	evolved	_	_	_	_
15-28	2031-2035	over	_	_	_	_
15-29	2036-2040	time	_	_	_	_
15-30	2041-2042	,	_	_	_	_
15-31	2043-2046	and	_	_	_	_
15-32	2047-2053	during	_	_	_	_
15-33	2054-2057	the	abstract[101]	giv[101]	_	_
15-34	2058-2063	phase	abstract[101]	giv[101]	_	_
15-35	2064-2069	where	_	_	_	_
15-36	2070-2073	the	abstract[103]	new[103]	coref	15-59[111_103]
15-37	2074-2078	cell	place|abstract[103]	giv|new[103]	coref	15-60
15-38	2079-2089	population	abstract[103]	new[103]	_	_
15-39	2090-2097	reached	_	_	_	_
15-40	2098-2099	a	abstract[104]	giv[104]	_	_
15-41	2100-2104	very	abstract[104]	giv[104]	_	_
15-42	2105-2109	high	abstract[104]	giv[104]	_	_
15-43	2110-2117	density	abstract[104]	giv[104]	_	_
15-44	2118-2119	,	_	_	_	_
15-45	2120-2127	through	_	_	_	_
15-46	2128-2138	monitoring	event[105]	new[105]	_	_
15-47	2139-2141	of	event[105]	new[105]	_	_
15-48	2142-2145	the	event[105]|abstract[108]	new[105]|giv[108]	_	_
15-49	2146-2151	final	event[105]|abstract[108]	new[105]|giv[108]	_	_
15-50	2152-2162	monoclonal	event[105]|abstract[108]	new[105]|giv[108]	_	_
15-51	2163-2171	antibody	event[105]|substance|abstract[108]	new[105]|giv|giv[108]	_	_
15-52	2172-2179	product	event[105]|substance|abstract[108]	new[105]|new|giv[108]	coref	16-22
15-53	2180-2193	concentration	event[105]|abstract[108]	new[105]|giv[108]	_	_
15-54	2194-2197	and	event[105]	new[105]	_	_
15-55	2198-2201	the	event[105]|abstract[109]	new[105]|new[109]	_	_
15-56	2202-2210	specific	event[105]|abstract[109]	new[105]|new[109]	_	_
15-57	2211-2223	productivity	event[105]|abstract[109]	new[105]|new[109]	_	_
15-58	2224-2226	of	event[105]|abstract[109]	new[105]|new[109]	_	_
15-59	2227-2230	the	event[105]|abstract[109]|abstract[111]	new[105]|new[109]|giv[111]	coref	19-25[141_111]
15-60	2231-2235	cell	event[105]|abstract[109]|place|abstract[111]	new[105]|new[109]|giv|giv[111]	coref	19-8
15-61	2236-2246	population	event[105]|abstract[109]|abstract[111]	new[105]|new[109]|giv[111]	_	_
15-62	2247-2248	.	_	_	_	_

#Text=This investigation aimed to determine which among the ten amino acids were critical for supporting health growth of the population and product formation .
16-1	2249-2253	This	event[112]	new[112]	_	_
16-2	2254-2267	investigation	event[112]	new[112]	_	_
16-3	2268-2273	aimed	_	_	_	_
16-4	2274-2276	to	_	_	_	_
16-5	2277-2286	determine	_	_	_	_
16-6	2287-2292	which	_	_	_	_
16-7	2293-2298	among	_	_	_	_
16-8	2299-2302	the	substance[114]	giv[114]	coref	18-12[131_114]
16-9	2303-2306	ten	substance[114]	giv[114]	_	_
16-10	2307-2312	amino	object|substance[114]	giv|giv[114]	coref	18-14
16-11	2313-2318	acids	substance[114]	giv[114]	_	_
16-12	2319-2323	were	_	_	_	_
16-13	2324-2332	critical	_	_	_	_
16-14	2333-2336	for	_	_	_	_
16-15	2337-2347	supporting	_	_	_	_
16-16	2348-2354	health	abstract|abstract[116]	new|new[116]	coref|coref	19-13[0_116]|19-13[0_116]
16-17	2355-2361	growth	abstract[116]	new[116]	_	_
16-18	2362-2364	of	abstract[116]	new[116]	_	_
16-19	2365-2368	the	abstract[116]|person[117]	new[116]|new[117]	_	_
16-20	2369-2379	population	abstract[116]|person[117]	new[116]|new[117]	_	_
16-21	2380-2383	and	abstract[116]	new[116]	_	_
16-22	2384-2391	product	abstract[116]|abstract|abstract[119]	new[116]|giv|new[119]	coref|coref|coref|coref	19-22|19-22[139_119]|19-22|19-22[139_119]
16-23	2392-2401	formation	abstract[116]|abstract[119]	new[116]|new[119]	_	_
16-24	2402-2403	.	_	_	_	_

#Text=In return , this information could be utilized for designing an amino acid supplementation regime , through which a superior culture could be achieved through medium improvements .
17-1	2404-2406	In	_	_	_	_
17-2	2407-2413	return	event	new	_	_
17-3	2414-2415	,	_	_	_	_
17-4	2416-2420	this	abstract[121]	new[121]	_	_
17-5	2421-2432	information	abstract[121]	new[121]	_	_
17-6	2433-2438	could	_	_	_	_
17-7	2439-2441	be	_	_	_	_
17-8	2442-2450	utilized	_	_	_	_
17-9	2451-2454	for	_	_	_	_
17-10	2455-2464	designing	_	_	_	_
17-11	2465-2467	an	abstract[124]	new[124]	_	_
17-12	2468-2473	amino	abstract[124]	new[124]	_	_
17-13	2474-2478	acid	substance|abstract[124]	giv|new[124]	coref	25-14
17-14	2479-2494	supplementation	abstract|abstract[124]	new|new[124]	_	_
17-15	2495-2501	regime	abstract[124]	new[124]	_	_
17-16	2502-2503	,	_	_	_	_
17-17	2504-2511	through	_	_	_	_
17-18	2512-2517	which	_	_	_	_
17-19	2518-2519	a	abstract[125]	giv[125]	coref	19-6[134_125]
17-20	2520-2528	superior	abstract[125]	giv[125]	_	_
17-21	2529-2536	culture	abstract[125]	giv[125]	_	_
17-22	2537-2542	could	_	_	_	_
17-23	2543-2545	be	_	_	_	_
17-24	2546-2554	achieved	_	_	_	_
17-25	2555-2562	through	_	_	_	_
17-26	2563-2569	medium	abstract[126]	new[126]	_	_
17-27	2570-2582	improvements	abstract[126]	new[126]	_	_
17-28	2583-2584	.	_	_	_	_

#Text=The authors proposed a two-stage strategy for providing the cells with the key amino acids .
18-1	2585-2588	The	person[127]	new[127]	_	_
18-2	2589-2596	authors	person[127]	new[127]	_	_
18-3	2597-2605	proposed	_	_	_	_
18-4	2606-2607	a	abstract[128]	giv[128]	coref	20-8[144_128]
18-5	2608-2617	two-stage	abstract[128]	giv[128]	_	_
18-6	2618-2626	strategy	abstract[128]	giv[128]	_	_
18-7	2627-2630	for	_	_	_	_
18-8	2631-2640	providing	_	_	_	_
18-9	2641-2644	the	object[129]	giv[129]	_	_
18-10	2645-2650	cells	object[129]	giv[129]	_	_
18-11	2651-2655	with	object[129]	giv[129]	_	_
18-12	2656-2659	the	object[129]|substance[131]	giv[129]|giv[131]	coref	20-16[146_131]
18-13	2660-2663	key	object[129]|substance[131]	giv[129]|giv[131]	_	_
18-14	2664-2669	amino	object[129]|object|substance[131]	giv[129]|giv|giv[131]	_	_
18-15	2670-2675	acids	object[129]|substance[131]	giv[129]|giv[131]	_	_
18-16	2676-2677	.	_	_	_	_

#Text=One stage focused on achieving a healthy cell culture through focusing on growth optimization , and a second stage which optimizes product formation once a large cell population has been achieved .
19-1	2678-2681	One	abstract[132]	new[132]	coref	19-17[137_132]
19-2	2682-2687	stage	abstract[132]	new[132]	_	_
19-3	2688-2695	focused	_	_	_	_
19-4	2696-2698	on	_	_	_	_
19-5	2699-2708	achieving	_	_	_	_
19-6	2709-2710	a	abstract[134]	giv[134]	_	_
19-7	2711-2718	healthy	abstract[134]	giv[134]	_	_
19-8	2719-2723	cell	place|abstract[134]	giv|giv[134]	coref	19-27
19-9	2724-2731	culture	abstract[134]	giv[134]	_	_
19-10	2732-2739	through	_	_	_	_
19-11	2740-2748	focusing	_	_	_	_
19-12	2749-2751	on	_	_	_	_
19-13	2752-2758	growth	abstract|abstract[136]	giv|giv[136]	coref|coref	20-20|20-20
19-14	2759-2771	optimization	abstract[136]	giv[136]	_	_
19-15	2772-2773	,	_	_	_	_
19-16	2774-2777	and	_	_	_	_
19-17	2778-2779	a	abstract[137]	giv[137]	_	_
19-18	2780-2786	second	abstract[137]	giv[137]	_	_
19-19	2787-2792	stage	abstract[137]	giv[137]	_	_
19-20	2793-2798	which	_	_	_	_
19-21	2799-2808	optimizes	_	_	_	_
19-22	2809-2816	product	abstract|abstract[139]	giv|giv[139]	_	_
19-23	2817-2826	formation	abstract[139]	giv[139]	_	_
19-24	2827-2831	once	_	_	_	_
19-25	2832-2833	a	abstract[141]	giv[141]	_	_
19-26	2834-2839	large	abstract[141]	giv[141]	_	_
19-27	2840-2844	cell	place|abstract[141]	giv|giv[141]	_	_
19-28	2845-2855	population	abstract[141]	giv[141]	_	_
19-29	2856-2859	has	_	_	_	_
19-30	2860-2864	been	_	_	_	_
19-31	2865-2873	achieved	_	_	_	_
19-32	2874-2875	.	_	_	_	_

#Text=More recently , Torkashvand et al. used the Plackett-Burman design to screen the effects of amino acids on promoting growth , and then optimized the medium concentrations of a combination of amino acids using response surface methodology to determine the feed composition .
20-1	2876-2880	More	_	_	_	_
20-2	2881-2889	recently	_	_	_	_
20-3	2890-2891	,	_	_	_	_
20-4	2892-2903	Torkashvand	person	new	_	_
20-5	2904-2906	et	_	_	_	_
20-6	2907-2910	al.	_	_	_	_
20-7	2911-2915	used	_	_	_	_
20-8	2916-2919	the	abstract[144]	giv[144]	coref	21-28[0_144]
20-9	2920-2935	Plackett-Burman	person|abstract[144]	giv|giv[144]	_	_
20-10	2936-2942	design	abstract[144]	giv[144]	_	_
20-11	2943-2945	to	_	_	_	_
20-12	2946-2952	screen	_	_	_	_
20-13	2953-2956	the	abstract[145]	giv[145]	_	_
20-14	2957-2964	effects	abstract[145]	giv[145]	_	_
20-15	2965-2967	of	abstract[145]	giv[145]	_	_
20-16	2968-2973	amino	abstract[145]|substance[146]	giv[145]|giv[146]	coref	20-32[150_146]
20-17	2974-2979	acids	abstract[145]|substance[146]	giv[145]|giv[146]	_	_
20-18	2980-2982	on	_	_	_	_
20-19	2983-2992	promoting	_	_	_	_
20-20	2993-2999	growth	abstract	giv	_	_
20-21	3000-3001	,	_	_	_	_
20-22	3002-3005	and	_	_	_	_
20-23	3006-3010	then	_	_	_	_
20-24	3011-3020	optimized	_	_	_	_
20-25	3021-3024	the	abstract[148]	giv[148]	_	_
20-26	3025-3031	medium	abstract[148]	giv[148]	_	_
20-27	3032-3046	concentrations	abstract[148]	giv[148]	_	_
20-28	3047-3049	of	abstract[148]	giv[148]	_	_
20-29	3050-3051	a	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
20-30	3052-3063	combination	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
20-31	3064-3066	of	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
20-32	3067-3072	amino	abstract[148]|abstract[149]|substance[150]	giv[148]|new[149]|giv[150]	_	_
20-33	3073-3078	acids	abstract[148]|abstract[149]|substance[150]	giv[148]|new[149]|giv[150]	_	_
20-34	3079-3084	using	_	_	_	_
20-35	3085-3093	response	abstract|abstract[153]	giv|giv[153]	_	_
20-36	3094-3101	surface	place|abstract[153]	giv|giv[153]	_	_
20-37	3102-3113	methodology	abstract[153]	giv[153]	_	_
20-38	3114-3116	to	_	_	_	_
20-39	3117-3126	determine	_	_	_	_
20-40	3127-3130	the	abstract[155]	giv[155]	coref	25-13[186_155]
20-41	3131-3135	feed	substance|abstract[155]	new|giv[155]	_	_
20-42	3136-3147	composition	abstract[155]	giv[155]	_	_
20-43	3148-3149	.	_	_	_	_

#Text=Although statistics were employed in these studies , it would be very difficult to extract learning as to the nature of the potential benefits of employing different design approaches since these investigations focused on the empirical aspects of the study rather than providing an in-depth evaluation of the statistical tools employed .
21-1	3150-3158	Although	_	_	_	_
21-2	3159-3169	statistics	abstract	new	_	_
21-3	3170-3174	were	_	_	_	_
21-4	3175-3183	employed	_	_	_	_
21-5	3184-3186	in	_	_	_	_
21-6	3187-3192	these	event[157]	giv[157]	_	_
21-7	3193-3200	studies	event[157]	giv[157]	_	_
21-8	3201-3202	,	_	_	_	_
21-9	3203-3205	it	substance	new	cata	21-9[0_159]
21-10	3206-3211	would	_	_	_	_
21-11	3212-3214	be	_	_	_	_
21-12	3215-3219	very	_	_	_	_
21-13	3220-3229	difficult	_	_	_	_
21-14	3230-3232	to	substance[159]	new[159]	_	_
21-15	3233-3240	extract	substance[159]	new[159]	_	_
21-16	3241-3249	learning	substance[159]	new[159]	_	_
21-17	3250-3252	as	_	_	_	_
21-18	3253-3255	to	_	_	_	_
21-19	3256-3259	the	_	_	_	_
21-20	3260-3266	nature	_	_	_	_
21-21	3267-3269	of	_	_	_	_
21-22	3270-3273	the	abstract[160]	new[160]	_	_
21-23	3274-3283	potential	abstract[160]	new[160]	_	_
21-24	3284-3292	benefits	abstract[160]	new[160]	_	_
21-25	3293-3295	of	_	_	_	_
21-26	3296-3305	employing	_	_	_	_
21-27	3306-3315	different	abstract[162]	new[162]	_	_
21-28	3316-3322	design	abstract|abstract[162]	giv|new[162]	_	_
21-29	3323-3333	approaches	abstract[162]	new[162]	_	_
21-30	3334-3339	since	_	_	_	_
21-31	3340-3345	these	abstract[163]	new[163]	_	_
21-32	3346-3360	investigations	abstract[163]	new[163]	_	_
21-33	3361-3368	focused	_	_	_	_
21-34	3369-3371	on	_	_	_	_
21-35	3372-3375	the	abstract[164]	new[164]	_	_
21-36	3376-3385	empirical	abstract[164]	new[164]	_	_
21-37	3386-3393	aspects	abstract[164]	new[164]	_	_
21-38	3394-3396	of	abstract[164]	new[164]	_	_
21-39	3397-3400	the	abstract[164]|abstract[165]	new[164]|giv[165]	_	_
21-40	3401-3406	study	abstract[164]|abstract[165]	new[164]|giv[165]	_	_
21-41	3407-3413	rather	_	_	_	_
21-42	3414-3418	than	_	_	_	_
21-43	3419-3428	providing	_	_	_	_
21-44	3429-3431	an	abstract[166]	new[166]	_	_
21-45	3432-3440	in-depth	abstract[166]	new[166]	_	_
21-46	3441-3451	evaluation	abstract[166]	new[166]	_	_
21-47	3452-3454	of	abstract[166]	new[166]	_	_
21-48	3455-3458	the	abstract[166]|abstract[167]	new[166]|new[167]	ana	22-3[0_167]
21-49	3459-3470	statistical	abstract[166]|abstract[167]	new[166]|new[167]	_	_
21-50	3471-3476	tools	abstract[166]|abstract[167]	new[166]|new[167]	_	_
21-51	3477-3485	employed	_	_	_	_
21-52	3486-3487	.	_	_	_	_

#Text=Consequently , they fail to compare and contrast different methods and provide reasoning for the selection of certain models over others , or point towards the utilization of favorable statistical designs , which could prove invaluable to attain systematic medium development strategies .
22-1	3488-3500	Consequently	_	_	_	_
22-2	3501-3502	,	_	_	_	_
22-3	3503-3507	they	abstract	giv	_	_
22-4	3508-3512	fail	_	_	_	_
22-5	3513-3515	to	_	_	_	_
22-6	3516-3523	compare	_	_	_	_
22-7	3524-3527	and	_	_	_	_
22-8	3528-3536	contrast	_	_	_	_
22-9	3537-3546	different	abstract[169]	giv[169]	coref	26-1[190_169]
22-10	3547-3554	methods	abstract[169]	giv[169]	_	_
22-11	3555-3558	and	_	_	_	_
22-12	3559-3566	provide	_	_	_	_
22-13	3567-3576	reasoning	abstract[170]	new[170]	_	_
22-14	3577-3580	for	abstract[170]	new[170]	_	_
22-15	3581-3584	the	abstract[170]|abstract[171]	new[170]|new[171]	_	_
22-16	3585-3594	selection	abstract[170]|abstract[171]	new[170]|new[171]	_	_
22-17	3595-3597	of	abstract[170]|abstract[171]	new[170]|new[171]	_	_
22-18	3598-3605	certain	abstract[170]|abstract[171]|abstract[172]	new[170]|new[171]|new[172]	_	_
22-19	3606-3612	models	abstract[170]|abstract[171]|abstract[172]	new[170]|new[171]|new[172]	_	_
22-20	3613-3617	over	abstract[170]|abstract[171]|abstract[172]	new[170]|new[171]|new[172]	_	_
22-21	3618-3624	others	abstract[170]|abstract[171]|abstract[172]|person	new[170]|new[171]|new[172]|new	_	_
22-22	3625-3626	,	abstract[170]|abstract[171]	new[170]|new[171]	_	_
22-23	3627-3629	or	abstract[170]|abstract[171]	new[170]|new[171]	_	_
22-24	3630-3635	point	abstract[170]|abstract[171]|abstract[174]	new[170]|new[171]|new[174]	_	_
22-25	3636-3643	towards	abstract[170]|abstract[171]|abstract[174]	new[170]|new[171]|new[174]	_	_
22-26	3644-3647	the	abstract[170]|abstract[171]|abstract[174]|abstract[175]	new[170]|new[171]|new[174]|giv[175]	_	_
22-27	3648-3659	utilization	abstract[170]|abstract[171]|abstract[174]|abstract[175]	new[170]|new[171]|new[174]|giv[175]	_	_
22-28	3660-3662	of	abstract[170]|abstract[171]|abstract[174]|abstract[175]	new[170]|new[171]|new[174]|giv[175]	_	_
22-29	3663-3672	favorable	abstract[170]|abstract[171]|abstract[174]|abstract[175]|abstract[176]	new[170]|new[171]|new[174]|giv[175]|new[176]	_	_
22-30	3673-3684	statistical	abstract[170]|abstract[171]|abstract[174]|abstract[175]|abstract[176]	new[170]|new[171]|new[174]|giv[175]|new[176]	_	_
22-31	3685-3692	designs	abstract[170]|abstract[171]|abstract[174]|abstract[175]|abstract[176]	new[170]|new[171]|new[174]|giv[175]|new[176]	_	_
22-32	3693-3694	,	_	_	_	_
22-33	3695-3700	which	_	_	_	_
22-34	3701-3706	could	_	_	_	_
22-35	3707-3712	prove	_	_	_	_
22-36	3713-3723	invaluable	_	_	_	_
22-37	3724-3726	to	_	_	_	_
22-38	3727-3733	attain	_	_	_	_
22-39	3734-3744	systematic	abstract[178]	new[178]	_	_
22-40	3745-3751	medium	abstract[178]	new[178]	_	_
22-41	3752-3763	development	event|abstract[178]	giv|new[178]	_	_
22-42	3764-3774	strategies	abstract[178]	new[178]	_	_
22-43	3775-3776	.	_	_	_	_

#Text=2.2 .
23-1	3777-3780	2.2	abstract	new	_	_
23-2	3781-3782	.	_	_	_	_

#Text=Metabolic Profiling
24-1	3783-3792	Metabolic	person|event[181]	new|new[181]	_	_
24-2	3793-3802	Profiling	event[181]	new[181]	_	_

#Text=Another method widely used in the industry to understand the impact of amino acid composition on mAb production is exo- and endo-metabolic profiling .
25-1	3803-3810	Another	abstract[182]	giv[182]	coref	25-20[189_182]
25-2	3811-3817	method	abstract[182]	giv[182]	_	_
25-3	3818-3824	widely	_	_	_	_
25-4	3825-3829	used	_	_	_	_
25-5	3830-3832	in	_	_	_	_
25-6	3833-3836	the	abstract[183]	new[183]	_	_
25-7	3837-3845	industry	abstract[183]	new[183]	_	_
25-8	3846-3848	to	_	_	_	_
25-9	3849-3859	understand	_	_	_	_
25-10	3860-3863	the	abstract[184]	new[184]	_	_
25-11	3864-3870	impact	abstract[184]	new[184]	_	_
25-12	3871-3873	of	abstract[184]	new[184]	_	_
25-13	3874-3879	amino	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
25-14	3880-3884	acid	abstract[184]|substance|abstract[186]	new[184]|giv|giv[186]	_	_
25-15	3885-3896	composition	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
25-16	3897-3899	on	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
25-17	3900-3903	mAb	abstract[184]|abstract[186]|substance|abstract[188]	new[184]|giv[186]|giv|giv[188]	_	_
25-18	3904-3914	production	abstract[184]|abstract[186]|abstract[188]	new[184]|giv[186]|giv[188]	_	_
25-19	3915-3917	is	_	_	_	_
25-20	3918-3922	exo-	abstract[189]	giv[189]	_	_
25-21	3923-3926	and	abstract[189]	giv[189]	_	_
25-22	3927-3941	endo-metabolic	abstract[189]	giv[189]	_	_
25-23	3942-3951	profiling	abstract[189]	giv[189]	_	_
25-24	3952-3953	.	_	_	_	_

#Text=Such methods are purely empirical and are mainly utilized to improve an established platform process , by suggesting specific nutrients to be added during the course of a cultivation , for example , rather than to conduct a broad de novo exploration .
26-1	3954-3958	Such	abstract[190]	giv[190]	_	_
26-2	3959-3966	methods	abstract[190]	giv[190]	_	_
26-3	3967-3970	are	_	_	_	_
26-4	3971-3977	purely	_	_	_	_
26-5	3978-3987	empirical	_	_	_	_
26-6	3988-3991	and	_	_	_	_
26-7	3992-3995	are	_	_	_	_
26-8	3996-4002	mainly	_	_	_	_
26-9	4003-4011	utilized	_	_	_	_
26-10	4012-4014	to	_	_	_	_
26-11	4015-4022	improve	_	_	_	_
26-12	4023-4025	an	abstract[192]	new[192]	_	_
26-13	4026-4037	established	abstract[192]	new[192]	_	_
26-14	4038-4046	platform	abstract|abstract[192]	new|new[192]	_	_
26-15	4047-4054	process	abstract[192]	new[192]	_	_
26-16	4055-4056	,	_	_	_	_
26-17	4057-4059	by	_	_	_	_
26-18	4060-4070	suggesting	_	_	_	_
26-19	4071-4079	specific	substance[193]	new[193]	_	_
26-20	4080-4089	nutrients	substance[193]	new[193]	_	_
26-21	4090-4092	to	_	_	_	_
26-22	4093-4095	be	_	_	_	_
26-23	4096-4101	added	_	_	_	_
26-24	4102-4108	during	_	_	_	_
26-25	4109-4112	the	abstract[194]	new[194]	_	_
26-26	4113-4119	course	abstract[194]	new[194]	_	_
26-27	4120-4122	of	abstract[194]	new[194]	_	_
26-28	4123-4124	a	abstract[194]|event[195]	new[194]|new[195]	_	_
26-29	4125-4136	cultivation	abstract[194]|event[195]	new[194]|new[195]	_	_
26-30	4137-4138	,	_	_	_	_
26-31	4139-4142	for	_	_	_	_
26-32	4143-4150	example	_	_	_	_
26-33	4151-4152	,	_	_	_	_
26-34	4153-4159	rather	_	_	_	_
26-35	4160-4164	than	_	_	_	_
26-36	4165-4167	to	_	_	_	_
26-37	4168-4175	conduct	_	_	_	_
26-38	4176-4177	a	event[196]	new[196]	_	_
26-39	4178-4183	broad	event[196]	new[196]	_	_
26-40	4184-4186	de	event[196]	new[196]	_	_
26-41	4187-4191	novo	event[196]	new[196]	_	_
26-42	4192-4203	exploration	event[196]	new[196]	_	_
26-43	4204-4205	.	_	_	_	_
